Biblio
Tisagenlecleucel cellular kinetics, dose, and immunogenicity in relation to clinical factors in relapsed/refractory DLBCL. Blood Adv. 2020;4(3):560-572.
Overall survival of cHL patients who progress after autologous stem cell transplant: results in novel agent era. Blood Adv. 2023.
Myeloablative Vs. Non-Myeloablative Consolidation for Primary Central Nervous System Lymphoma: Results of Alliance 51101. Blood Adv. 2024.
Assessing Early Supportive Care Needs Among Son or Daughter Haploidentical Transplantation Donors. Biol Blood Marrow Transplant. 2020.
.